停用非布司他或别嘌醇后初期阶段心血管事件和死亡风险增加:CARES试验的另一面
基于CARES试验数据,在6190例痛风患者中比较服药期间与停药后初期主要不良心血管事件(MACE)及心血管死亡。停药后MACE发生率较服药期间显著升高,停药后6个月内CV死亡率高于非CV死亡率,且停药前血尿酸变化与停药后MACE风险升高相关。
要点
- 停药后MACE发生率为6.71/100人年,服药期间为3.11/100人年。
- 停药后1个月内MACE风险较服药期间升高(HR 7.40;95%CI 5.38至10.17)。
- 停药后6个月内CV死亡率45.7%高于非CV死亡率27.9%(p=0.0001)。
核心结论
- 痛风患者停用非布司他或别嘌醇后初期阶段MACE和心血管死亡增加。
研究设计与样本
- 利用CARES试验数据,比较服药期间与停药后初期MACE,并比较停药后初期CV与非CV死亡率,共纳入6190例患者。
主要发现
- MACE每100人年发生率服药期间为3.11,停药后为6.71。
- 停药后1个月内MACE较服药期间显著升高(HR 7.40;95%CI 5.38至10.17)。
- 停药后6个月内MACE较服药期间显著升高(HR 5.22;95%CI 4.26至6.39)。
- 排除末次用药后1天内不良事件所致死亡的分析中,6个月内CV死亡率45.7%高于非CV死亡率27.9%(p=0.0001)。
- 基线至停药前末次测量的血尿酸变化与停药后更高MACE风险显著相关(HR 1.14;95%CI 1.04至1.26)。
关键数值与推荐
- MACE发生率:服药期间3.11/100人年 vs 停药后6.71/100人年。
- 停药后1个月内MACE:HR 7.40(95%CI 5.38至10.17)。
- 停药后6个月内MACE:HR 5.22(95%CI 4.26至6.39)。
- 6个月内CV死亡率45.7% vs 非CV死亡率27.9%(p=0.0001)。
- 血尿酸变化与停药后MACE:HR 1.14(95%CI 1.04至1.26)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: The Cardiovascular Safety of Febuxostat or Allopurinol in Patients with Gout (CARES) trial suggested a higher risk of cardiovascular (CV) death from febuxostat than from allopurinol. However, a significant number of patients died after discontinuation of febuxostat or allopurinol. We investigated whether major adverse cardiovascular events (MACE) and CV death were increased because of discontinuation of febuxostat or allopurinol using the CARES trial data. METHODS: We compared the MACE that occurred during administration and after discontinuation in the initial phase after discontinuation, and we compared the CV and non-CV mortality rates in the initial phase after discontinuation to determine the impact of discontinuation of febuxostat or allopurinol. RESULTS: Among 6190 patients, the incidence rate per 100 person-years for MACE was 3.11 during administration and 6.71 after discontinuation. MACE was significantly increased after discontinuation compared with that during administration within 1 month (HR 7.40; 95% CI 5.38 to 10.17) and 6 months (HR 5.22; 95% CI 4.26 to 6.39). In the analysis excluding death induced by adverse events that occurred up to 1 day after the last medication, the CV mortality rate was higher than the non-CV mortality rate within 6 months (45.7% vs 27.9%, p=0.0001). In addition, changes in serum uric acid levels from baseline to the last measurement before discontinuation were significantly associated with higher MACE risk after drug discontinuation (HR 1.14; 95% CI 1.04 to 1.26). CONCLUSIONS: MACE and CV death were increased in the initial stage after discontinuation of febuxostat or allopurinol in patients with gout.
引用
- Ghang BZ, Lee JS, Choi J, et al. Increased risk of cardiovascular events and death in the initial phase after discontinuation of febuxostat or allopurinol: another story of the CARES trial. RMD Open. 2022. PMID: 35732345. doi:10.1136/rmdopen-2021-001944
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。